Potassium time-in-target range

There is 1 paper on potassium time-in-target range in aging research: 1 observational study in people.

Biomarker

1 paper studies it3 findings

1 new paper in 30 daysSee all 1 papers on potassium time-in-target range

“Doubling in potassium TIR was associated with a 20% lower risk of the composite outcome (HR 0.80, 95% CI 0.70-0.92, P=0.001).”
Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART AnalysisAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.13852
  • Humans1

Interventions

1

Finerenone

upin humans1

1 study
  1. Finerenone increases potassium time-in-target range in humans (Compared with placebo; potassium target range 4.5-5.0 mmol/L) (8% (95% CI 7-9); median 38% vs. 23%).

    “Randomization to finerenone increased TIR by 8% (95% CI 7-9) compared with placebo”

    Human trialCompared with placebo; potassium target range 4.5-5.0 mmol/Lfirst year35% womensn = 18,991

    Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

    AHA Scientific Sessions 2026 abstract

More on Finerenone

Associations

2

Cardiovascular death

downin humans1

1 study
  1. Potassium time-in-target range is associated with cardiovascular death in humans (Higher time within serum potassium range 4.5-5.0 mmol/L) (P=0.042).

    “which appeared driven by lower risks of CV death (P=0.042; Fig 2B) compared with HF hospitalization (P=0.23; Fig 2C).”

    HumansHigher time within serum potassium range 4.5-5.0 mmol/LTime-in-target range during the first year; subsequent outcomes35% womensn = 18,991

    Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

    AHA Scientific Sessions 2026 abstract

First heart failure hospitalization or cardiovascular death

downin humans1HR 0.8

1 study
  1. Potassium time-in-target range is associated with first heart failure hospitalization or cardiovascular death in humans (Per doubling of time within serum potassium range 4.5-5.0 mmol/L) (20% lower risk per doubling; HR 0.80, 95% CI 0.70-0.92, P=0.001).

    “Doubling in potassium TIR was associated with a 20% lower risk of the composite outcome (HR 0.80, 95% CI 0.70-0.92, P=0.001).”

    HumansPer doubling of time within serum potassium range 4.5-5.0 mmol/LTime-in-target range during the first year; subsequent outcomes35% womensn = 18,991

    Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

    AHA Scientific Sessions 2026 abstract

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months